Predictive Potential of suPAR in Mortality Assessment for Suspected Myocardial Infarction Patients

Mon Apr 08 2019

In a recent publication in Clinical Research in Cardiology, Sörensen NA et al. unveil the vital role of soluble urokinase plasminogen activator receptor (suPAR) as a predictive biomarker for suspected myocardial infarction.

Key Findings:

Their study focused on assessing suPAR levels to predict mortality risks in patients presenting symptoms of myocardial infarction in the emergency department. The results underscore suPAR’s significance in risk stratification for this high-risk group.

Comparing suPAR to the GRACE Score:

The study intriguingly compares suPAR’s predictive power to the widely recognized GRACE Score, a tool for forecasting 6-month outcomes in acute coronary syndrome patients. SuPAR proves equally effective as the GRACE Score.

Notable Observation:

While suPAR didn’t significantly improve risk categorization compared to the GRACE Score, the study’s finding that a single biomarker can rival a multifaceted score is remarkable. SuPAR demonstrates potential as a sole predictor of mortality in patients with suspected myocardial infarction.

In summary, Sörensen NA et al.’s study highlights suPAR’s potential as a robust biomarker for predicting mortality in such patients. This groundbreaking research not only refines risk assessment but also challenges traditional approaches to prognostic evaluation in acute coronary events. As the medical landscape evolves, suPAR is reshaping the future of cardiac care. Stay tuned for more developments in this field.

Link to abstract here


published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution


For Automated Systems


Clinical and Research

suPARnostic POC+


Point-of-care finger prick

suPAR is used in clinical routine in 48 hospitals

48 hospitals use suPAR in clinical routine for triage of patients in the Emergency Departments and COVID-19 units. Clinical routine is defined by the placement of two Purchasing Orders within the last 12 months rolling.
This period covers January 1, 2022, until December 31, 2022. Some hospital locations cannot be disclosed due to confidentiality.

New Webinar


Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates